Kylonova (Xiamen) Biopharma Co., Ltd. is mainly engaged in the research and development of new drugs and delivery platforms for siRNA (small interfering nucleic acids). The company has established three delivery platforms for siRNA with proprietary technologies, including Nano-Lipid Particle(NPDP) , a Multi-Valent Import platform (MVIP) and  Lipid-Coupling Delivery platform(LCDP). The technologies and quality standards of three delivery platforms are on the cutting-edge in the same fields, and can be scaled-up and manufactured for commercialization. Kylonova also performssolid phase oligonucleotide synthesis and DNA and RNA API production and can supply a contract manufacture.

Based on the established platforms, Kylonova is currently focusing on the development of RNAi therapeutics for liver-related diseases such as chronic hepatitis B (HBV), liver cancer and non-alcoholic fatty liver disease (NAFLD). Kylonova has a scientific team from overseas in this field with more than 30 patents/patent applications, 18 of which have been approved. These patents covered the compounds, uses, preparation processes and formulation compositions and prescription etc.